Age, Sex, andAPOEε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span DOI Open Access
Clifford R. Jack,

Heather J. Wiste,

Stephen D. Weigand

et al.

JAMA Neurology, Journal Year: 2015, Volume and Issue: 72(5), P. 511 - 511

Published: March 16, 2015

Typical cognitive aging may be defined as age-associated changes in performance individuals who remain free of dementia. Ideally, the full adult age spectrum should included to assess brain imaging findings associated with typical aging.To compare age, sex, and APOE ε4 effects on memory, structure (adjusted hippocampal volume [HVa]), amyloid positron emission tomography (PET) cognitively normal aged 30 95 years old.Cross-sectional observational study (March 2006 October 2014) at an academic medical center. We studied 1246 individuals, including 1209 participants 50 old enrolled a population-based 37 self-selected volunteers 49 old.Memory, HVa, PET.Overall, memory worsened from through 90s. The HVa gradually mid-60s more steeply beyond that age. median PET was low until 70 increased thereafter. Memory worse men than women overall (P < .001) specifically 40 years. lower 60 There no sex difference any Within each were not different by status From onward, carriers had significantly greater noncarriers. However, ages which 10% population positive 57 for 64 noncarriers.Male is among while not. In contrast, (from onward), Worsening occur earlier abnormal PET. Therefore, neuropathological processes other β-amyloidosis must underlie declines function middle Our are consistent model late-onset Alzheimer disease arises later life background preexisting structural decline β-amyloid deposits.

Language: Английский

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease DOI Creative Commons
Clifford R. Jack, David A. Bennett, Kaj Blennow

et al.

Alzheimer s & Dementia, Journal Year: 2018, Volume and Issue: 14(4), P. 535 - 562

Published: April 1, 2018

In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for preclinical, mild cognitive impairment, dementia stages of disease. Scientific progress in interim led to an initiative by update unify 2011 guidelines. This unifying is labeled a "research framework" because its intended use observational interventional research, not routine clinical care. Research Framework, disease (AD) defined underlying pathologic processes that can be documented postmortem examination or vivo biomarkers. The diagnosis based consequences (i.e., symptoms/signs) this research framework, which shifts definition AD living people from syndromal biological construct. framework focuses with biomarkers persons. Biomarkers are grouped into those β amyloid deposition, tau, neurodegeneration [AT(N)]. ATN classification system groups different (imaging biofluids) process each measures. AT(N) flexible new added three existing groups, biomarker beyond when they become available. We focus as continuum, staging may accomplished using continuous However, we also outline two categorical schemes severity impairment: scheme traditional categories six-stage numeric scheme. It important stress seeks create common language investigators generate test hypotheses about interactions among (denoted biomarkers) symptoms. appreciate concern biomarker-based has potential misused. Therefore, emphasize, first, it premature inappropriate general medical practice. Second, should used restrict alternative approaches hypothesis testing do There will situations where available requiring them would counterproductive specific goals (discussed more detail later document). Thus, considered template all age-related impairment dementia; rather, applied fit purpose study. Importantly, examined diverse populations. Although possible β-amyloid plaques neurofibrillary tau deposits causal pathogenesis, these abnormal protein define unique neurodegenerative disorders lead dementia. envision defining construct enable accurate characterization understanding sequence events associated AD, well multifactorial etiology approach precise trials pathways targeted appropriate people.

Language: Английский

Citations

7778

Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association DOI Creative Commons
Salim S. Virani, Álvaro Alonso, Emelia J. Benjamin

et al.

Circulation, Journal Year: 2020, Volume and Issue: 141(9)

Published: Jan. 29, 2020

The American Heart Association, in conjunction with the National Institutes of Health, annually reports on most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs).The through its Statistics Committee, continuously monitors evaluates sources stroke United States provide current information available annual Update. 2020 is product full year's worth effort by dedicated volunteer clinicians scientists, committed government professionals, Association staff members. This edition includes monitoring benefits population, metrics assess monitor healthy diets, an enhanced focus social determinants health, global burden further evidence-based approaches changing behaviors, implementation strategies, implications Association's Impact Goals.Each 26 chapters focuses different topic statistics.The represents critical resource for lay public, policy makers, media clinicians, healthcare administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

Citations

7738

The amyloid hypothesis of Alzheimer's disease at 25 years DOI Creative Commons
Dennis J. Selkoe, John Hardy

EMBO Molecular Medicine, Journal Year: 2016, Volume and Issue: 8(6), P. 595 - 608

Published: March 29, 2016

Review29 March 2016Open Access The amyloid hypothesis of Alzheimer's disease at 25 years Dennis J Selkoe Ann Romney Center for Neurologic Diseases, Department Neurology, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA Search more papers by this author John Hardy Corresponding Author Reta Lila Weston Institute Molecular Neuroscience, UCL London, UK Information Selkoe1,‡ 2,‡ 1Ann 2Reta ‡These authors contributed equally to work *Corresponding author. Tel: +44 203 108 7466; E-mail: [email protected] EMBO Mol Med (2016)8:595-608https://doi.org/10.15252/emmm.201606210 See the Glossary abbreviations used in article. PDFDownload PDF article text main figures. ToolsAdd favoritesDownload CitationsTrack CitationsPermissions Figures & Info Abstract Despite continuing debate about β-protein (or Aβ hypothesis, new lines evidence from laboratories clinics worldwide support concept that an imbalance between production clearance Aβ42 related peptides is a very early, often initiating factor (AD). Confirmation presenilin catalytic site γ-secretase has provided linchpin: all dominant mutations causing early-onset AD occur either substrate (amyloid precursor protein, APP) or protease (presenilin) reaction generates Aβ. Duplication wild-type APP gene Down's syndrome leads deposits teens, followed microgliosis, astrocytosis, neurofibrillary tangles typical AD. Apolipoprotein E4, which predisposes > 40% cases, been found impair brain. Soluble oligomers isolated patients' brains can decrease synapse number, inhibit long-term potentiation, enhance synaptic depression rodent hippocampus, injecting them into healthy rats impairs memory. human also induce hyperphosphorylation tau AD-relevant epitopes cause neuritic dystrophy cultured neurons. Crossing with transgenic mice enhances tau-positive neurotoxicity. In humans, studies show low cerebrospinal fluid (CSF) amyloid-PET positivity precede other manifestations many years. Most importantly, recent trials three different antibodies (solanezumab, crenezumab, aducanumab) have suggested slowing cognitive decline post hoc analyses mild subjects. Although factors contribute pathogenesis, dyshomeostasis emerged as most extensively validated compelling therapeutic target. Microgliosis early non-specific proliferation migration microglial cells, macrophage-like cells central nervous system, first response brain damage. Astrocytosis final damage injury astrocytes, type glial cell responsible maintaining extracellular ion neurotransmitter concentrations, modulating function, forming blood–brain barrier. Neurofibrillary accumulation hyperphosphorylated commonly disease, aggregates inside nerve bodies, known dystrophic neurites. Plaque deposition fibrils are deposited outside neurons dense formations, senile plaques plaques. FAD familial caused inherited (typically early-onset) opposition "sporadic" late-onset Introduction Few problems modern biomedicine garnered much scientific interest public concern disease. Virtually unknown general four decades ago, risen prevalence estimated 40 million patients worldwide. true number must be higher, given increasing recognition begins least 2–3 before one forgets name grandchild where parked one's car. Since molecular began earnest 1980s, thousands scientists healthcare professionals delved aspects complex, multifactorial syndrome, hoping help now prevent others developing it future. progressive buildup amyloids diverse protein composition various systemic organs devastating diseases than century, idea put forward George Glenner (Glenner Wong, 1984) particular amyloidogenic accumulating (Aβ) could causative met considerable skepticism over ensuing Precisely why so controversial not clear (Selkoe, 2011), but steady accrual data preclinical clinical increasingly supported it. Aβ) (Beyreuther Masters, 1991; Allsop, Selkoe, Higgins, 1992) become model pathogenesis guiding development potential treatments. We reviewed (Fig 1) dozen ago (Hardy 2002). Space precludes full examination here enormous literature on since review; monograph pathobiology contains details (Selkoe et al, 2012). But context yet emergence apparently positive trial data, critical analysis latest developments laboratory clinic warranted timely. review numerous our prior ever-increasing effort being expended. summarize salient findings undergird (Box 1), we discuss several alternative concepts concerns counterposed (Table 1). Box 1: Evidence supporting key role All undergo surrounding cytopathology regions serving memory cognition. Mutations within immediately flanking region aggressive forms FAD. Humans trisomy 21 (Down's syndrome) harbor 3 copies invariably develop neuropathologically Those who die their early-to-mid teens (from causes) abundant diffuse without dystrophy, tangle formation, accrue gradually such subjects late beyond. Inheritance missense mutation decreases aggregation lifelong protects against age-related decline. Missense 1 2 common AD, subunit γ-secretase. result relative increases Aβ42/43 peptides. These hydrophobic species self-aggregate, leading profound mid-life. ApoE4 carriers were once included This allele was markedly increase risk Aβ, excess downstream neuropathology. (late-onset) density, LTP, intraventricular injection adult rats. Human rat neurons; co-administering fully prevents this. penumbra around Accordingly, centrifugal gradient: less abnormality longer distances plaque edge. Based biomarker studies, CSF scans AD-related changes (increased tau, decreased cerebral glucose metabolism, atrophy, dementia) Trials monoclonal (but moderate) patients. Other proteins proven organ failure, lowering its yields benefits Figure 1. sequence major pathogenic events proposed cascade hypothesisThe curved blue arrow indicates may directly injure synapses neurites neurons, addition activating microglia astrocytes. Download figure PowerPoint Table Findings appear undercut counterarguments explain these discrepancies Counterarguments Amyloid burden correlates well degree impairment do counts widespread event distant dementia lead cellular (e.g., tangles, etc.) proximate neuronal dysfunction Many humans sometimes death noticeably demented Some (not rich abnormal glia); tested rigorously death; oligomer levels per lower (Esparza 2013), suggesting effectively sequester non-diffusible, neurotoxic state, up point neuropathological suggest Such searched systematically soluble genetics proves Aβ-elevating alteration whereas amyloid-related A fundamentally due loss function AD-causing indeed act through partial protease, heterozygous produce clinically detectable Notch phenotypes), organismal normal until symptoms mid-life, heralded elevated Aβ40 ratios. Moreover, 99.9% presenilins Numerous anti-amyloid agents pre-specified endpoints Several had inadequate poor penetration, little change, and/or indexes tramiprosate; R-flurbiprofen; semagacestat). failed enrolled late-mild moderate stages conducted produced suggestive benefit. done obligatory imaging turned out ~25% amyloid-negative (i.e., did AD) New insights homeostasis fact alter proteolytic processing way elevates Aβ43 long (Scheuner 1996; NB: lie self-aggregation resultant peptides, production). mechanistic explanation discovery genes encode active intramembrane-cleaving enzyme (De Strooper 1998; Wolfe 1999). Subsequent begun illuminate how mediates intramembrane proteolysis (Qi-Takahara 2005; Takami 2009; Chavez-Gutierrez 2012; Okochi 2013; Fernandez 2014): initial endopeptidase cleavage near transmembrane/cytoplasmic interface (the ε-cleavage) multiple carboxypeptidase cleavages each sequentially removes 4 C-terminal amino acids approximately turn helix) 2). process two product start Aβ48/49 Aβ49/50 ε-cleavage. precise effects differ somewhat, cases C- N-terminal "processivity" thus (more self-aggregating) elegant provides biochemical earlier showing Aβ42/Aβ40 ratio humans. γ-Secretase reactions presenilin-mutant tissue showed studied carboxypeptidase-like activity, assays few similar processivity might some non-presenilin-mutant (Szaruga 2015). Aβ42, Aβ43, highly self-aggregating, actually anti-amyloidogenic (Kim 2007). 2. Progressive transmembrane domain Presenilin/γ-secretase complex One group emphasized aforementioned mechanism represents neural phenotype independent (Shen Kelleher, 2007; Xia They presenilin-1 generally hardly raise levels, overlook elevation species, (Saito 2011). interpreted perspective, pinpointing aspartyl allows instead speak terms functional shift principal bonds (Kretner 2016). heterozygotes experience no cleavage; rather, they accelerated precedes AD-typical syndrome. 99% (including disease) express presenilin, cannot pathogenesis. original formulation based part chromosome 21, implying individuals Alzheimer neuropathology because too lifelong. supposition substantiated identification segmental microduplications sub-regions 21. Rare translocation involving only distal telomeric features get (Prasher 1998). Conversely, those rare micro-duplicated rest typically mid-50s (Rovelet-Lecrux 2006). conclusively overexpression causes Even remarkable (A673T) second acid results β-secretase (Jonsson benefit compounded, mutant peptide generated altered properties (Benilova 2014; Maloney Zheng A673T even 2012), age 100 (Kero 2013). reduced resulting AD-protective strongly supports hypothesis. Improved modeling systems Concern expressed limitations available models β-amyloid pathogenicity Early mouse (e.g. Games 1995; Hsiao 1996) suffered reliance high transgene expression drive lack death. FAD-mutant MAPT (tau) (tg) succeeded augmenting pathology tangle-like accumulation, involved (Lewis 2001). Recently, gradual developed judicious use selective knockin endogenous 2014). stem cell-derived skin biopsies then absence (Shi Choi Muratore Moore 2015) formation tau. progress means able substantial culture. both models, extensive neurotoxicity dependent (Rapoport 2002; Jin 2011; Roberson Toward complete Year System Achievement Critique References 1995 Pathology Overexpression, al (1995) 2000 Tangle Overexpression: Lewis (2000) 2001 X Overexpression transgenes: artificiality (2001) 2012 derived Diffuse pathology: pre-tangles Not Shi (2012) 2014 Complex genome Artificiality mutations: Saito (2014) gel system Convincing 2015 PSEN (2015) Cell biology importance discovered 1993 (Corder 1993), advent genomewide association and, recently, exome sequencing loci discovered. Whereas recently described usually weaker effect (Lambert 2013) rarer (Guerreiro Jonsson ApoE4, helped delineate additional biological processes Three types especially important: cholesterol/sterol metabolism; inflammation brain's innate immune system; endosomal vesicle recycling (Jones 2010). E components metabolism cholesterol suspected, genetic implication ApoE contrasting loading depletion tg (Refolo 2000, Work expressing alleles shown influence involves differential isoform (Castellano 2011: discussed below). ABCA7 lipid transporter identified locus (Hollingworth loss-of-function threefold (Steinberg microglia, peripheral macrophages, normally promotes efflux lipids apolipoproteins regulates phagocytosis. knockout hAPP doubling insoluble changing processing, like ApoE, However, need pinpointed. Neuropathologists including important For example, observation elements classical complement (McGeer 1989) prescient. last years, variability determinant risk, implicating immunity investigated detail: Complement Receptor (CR1; Lambert 2009), CD33 (Bertram 2008), TREM2, indirectly deposition. Blockade CR1 inhibits activation potentiates phagocytosis (Crehan Inactivation primary uptake (Griciuc TREM2 sustaining (Wang Thus, genetically implicated helping maintain phagocytosing deposits. increased during 2013, Wang 2015; Matarin go load increases, useful (Suárez-Calvet emerging CNS (Forabosco Zhang Type single-transmembrane receptor principally exclusively undergoes ADAM/γ-secretase (Wunderlich Kleinberger 2014), incompletely understood [reviewed (Lue 2015)]. mutation, R47H, same extent does although upregulation subset Guerreiro suggests compromised development. current R47H AD-associated confer microglia. Deleting significantly associated (Ulrich burden, neuroinflammation, loss, spatial deficits (Jiang And transport surface shedding, impaired phagocytic (Kleinberger latter led shed ectodomain mutations. Endosomal set map regulating category includes SORL1, BIN1, PICALM (Rogaeva Zhao SORL1 previously (Andersen 2005), carrying haplotype confirmed (Young Likewise, appears (Kanatsu addition, across barrier: induced pluripotent (iPSC)-derived endothelial exhibited higher enhanced (Zhao summary, linking (previously "sporadic") provide driving avenues intervention, intervening Recent resolve controversies Connecting tangles: temporal canonical lesions Alois noted his 1906 index case debated ever since. An histopathological staging created Braak (1991) widely establish severity scale progression AD-type cytoskeletal changes, is, neurites, unrelated (it include oligomeric Aβ). detection modest amounts change limbic young middle-aged dying imply would necessarily lived longer. Instead, answer Inherited generation) (Lemere 1996a,b; Bateman 2012) tangles/neurites containing filaments clearly contrast, form frontotemporal subsequent deposition, converse demonstrated Laboratory sequence. hTau substantially behavioral offspring when (Roberson Treating culture cortex hyperphosphorylation, ensues if knocked down (Jin Aβ—particularly (Shankar 2008)—can trigger alterations, indicated. seems "permissive", enabling certain consequences (Maruyama How AD: chronically Aß vascular ApoE3 (Rebeck engineered (Holtzman 2000). detailed quantitative study using vivo microdialysis × hApoE crossed production) E3 E2, closely paralleling observed any contributes differentially sol

Language: Английский

Citations

5117

Heart Disease and Stroke Statistics—2021 Update DOI Creative Commons
Salim S. Virani, Álvaro Alonso, Hugo J. Aparicio

et al.

Circulation, Journal Year: 2021, Volume and Issue: 143(8)

Published: Jan. 27, 2021

The American Heart Association, in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data on a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs).The through its Statistics Committee, continuously monitors evaluates sources stroke United States provide current information available annual Update. 2021 is product full year's worth effort by dedicated volunteer clinicians scientists, committed government professionals, Association staff members. This edition includes monitoring benefits population, an enhanced focus social determinants health, adverse pregnancy outcomes, vascular contributions brain global burden further evidence-based approaches changing disease.Each 27 chapters focuses different topic statistics.The represents critical resource for lay public, policy makers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

Citations

4712

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies DOI Creative Commons
Justin M. Long, David M. Holtzman

Cell, Journal Year: 2019, Volume and Issue: 179(2), P. 312 - 339

Published: Sept. 26, 2019

Language: Английский

Citations

2351

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria DOI

Bruno Dubois,

Harald Hampel, Howard Feldman

et al.

Alzheimer s & Dementia, Journal Year: 2016, Volume and Issue: 12(3), P. 292 - 323

Published: March 1, 2016

During the past decade, a conceptual shift occurred in field of Alzheimer's disease (AD) considering as continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible identify even at preclinical stage before occurrence first clinical symptoms. This AD has become major focus postulates that early intervention may offer best chance therapeutic success. To date, very little evidence established on this "silent" disease. A clarification needed about definitions lexicon, limits, natural history, markers progression, ethical consequence detecting asymptomatic stage. article aimed addressing all different issues by providing for each them an updated review literature evidence, with practical recommendations.

Language: Английский

Citations

1638

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers DOI Creative Commons
Clifford R. Jack, David A. Bennett, Kaj Blennow

et al.

Neurology, Journal Year: 2016, Volume and Issue: 87(5), P. 539 - 547

Published: July 2, 2016

Biomarkers have become an essential component of Alzheimer disease (AD) research and because the pervasiveness AD pathology in elderly, same biomarkers are used cognitive aging research. A number current issues suggest that unbiased descriptive classification scheme for these would be useful. We propose "A/T/N" system which 7 major divided into 3 binary categories based on nature pathophysiology each measures. "A" refers to value a β-amyloid biomarker (amyloid PET or CSF Aβ42); "T," tau (CSF phospho tau, PET); "N," neurodegeneration neuronal injury ([(18)F]-fluorodeoxyglucose-PET, structural MRI, total tau). Each category is rated as positive negative. An individual score might appear A+/T+/N-, A+/T-/N-, etc. The A/T/N includes new modality PET. It agnostic temporal ordering mechanisms underlying pathogenesis. all individuals any population regardless mix findings therefore suited studies aging. does not specify labels thus diagnostic system. categorizing multidomain at person level format easy understand use. Given present lack consensus among specialists terminology across clinically normal dementia spectrum, will broadest acceptance if it independent from one defined scheme.

Language: Английский

Citations

1500

Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease DOI Open Access

Eric Tönnies,

Eugenia Trushina

Journal of Alzheimer s Disease, Journal Year: 2017, Volume and Issue: 57(4), P. 1105 - 1121

Published: Jan. 6, 2017

Alzheimer's disease (AD) is a devastating neurodegenerative disorder without cure. Most AD cases are sporadic where age represents the greatest risk factor. Lack of understanding mechanism hinders development efficacious therapeutic approaches. The loss synapses in affected brain regions correlates best with cognitive impairment patients and has been considered as early that precedes neuronal loss. Oxidative stress recognized contributing factor aging progression multiple diseases including AD. Increased production reactive oxygen species (ROS) associated age- disease-dependent mitochondrial function, altered metal homeostasis, reduced antioxidant defense directly affect synaptic activity neurotransmission neurons leading to dysfunction. In addition, molecular targets by ROS include nuclear DNA, lipids, proteins, calcium dynamics cellular architecture, receptor trafficking endocytosis, energy homeostasis. Abnormal metabolism turn could accumulation amyloid-β (Aβ) hyperphosphorylated Tau protein, which independently exacerbate dysfunction production, thereby vicious cycle. While mounting evidence implicates etiology, clinical trials therapies have not produced consistent results. this review, we will discuss role oxidative AD, innovative strategies evolved based on better complexity mechanisms dual play health disease.

Language: Английский

Citations

1455

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia DOI Open Access
Willemijn J. Jansen, Rik Ossenkoppele,

Dirk L. Knol

et al.

JAMA, Journal Year: 2015, Volume and Issue: 313(19), P. 1924 - 1924

Published: May 19, 2015

Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence amyloid pathology persons without are needed to understand development AD and design prevention studies.

Language: Английский

Citations

1381

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies DOI
Yu Yamazaki, Na Zhao, Thomas R. Caulfield

et al.

Nature Reviews Neurology, Journal Year: 2019, Volume and Issue: 15(9), P. 501 - 518

Published: July 31, 2019

Language: Английский

Citations

1036